RU2006134026A - Производные гетероарилалкилкарбаматов, их получение и их применение в качестве ингибиторов фермента faah - Google Patents
Производные гетероарилалкилкарбаматов, их получение и их применение в качестве ингибиторов фермента faah Download PDFInfo
- Publication number
- RU2006134026A RU2006134026A RU2006134026/04A RU2006134026A RU2006134026A RU 2006134026 A RU2006134026 A RU 2006134026A RU 2006134026/04 A RU2006134026/04 A RU 2006134026/04A RU 2006134026 A RU2006134026 A RU 2006134026A RU 2006134026 A RU2006134026 A RU 2006134026A
- Authority
- RU
- Russia
- Prior art keywords
- ethyl
- oxazolidinedione
- group
- formula
- pyridinyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
- C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
- C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C271/12—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
- C07D213/40—Acylated substituent nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/04—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to the ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
- C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
- C07D217/14—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/26—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D261/14—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D273/00—Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00
- C07D273/02—Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00 having two nitrogen atoms and only one oxygen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Urology & Nephrology (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Cardiology (AREA)
- Psychiatry (AREA)
- Heart & Thoracic Surgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Anesthesiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Otolaryngology (AREA)
- Virology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
1. Соединение, отвечающее общей формуле (I)в которойА выбран из одной или нескольких групп X, Y и/или Z;X означает метиленовую группу, необязательно замещенную одной или двумя группами, представляющими C-алкил, C-циклоалкил или C-циклоалкил-C-алкилен;Y означает или C-алкениленовую группу, необязательно замещенную одной или двумя группами, представляющими C-алкил, C-циклоалкил или C-циклоалкил-C-алкилен; или C-алкиниленовую группу;Z означает группу формулы:m означает целое число от 1 до 5;p и q означают целые числа и определены так, что p+q является числом от 1 до 5;n означает целое число от 1 до 7;Rозначает группу R, необязательно замещенную одной или несколькими группами Rи/или R;Rозначает группу, выбранную из пиридинила, пиримидинила, пиридазинила, пиразинила, триазинила, пирролила, фуранила, тиенила, имидазолила, оксазолила, тиазолила, пиразолила, изоксазолила, изотиазолила, оксадиазолила, тиадиазолила, триазолила, тетразолила, нафтила, хинолинила, тетрагидрохинолинила, изохинолинила, тетрагидроизохинолинила, 2-оксо-3,4-дигидрохинолинила, 1-оксо-3,4-дигидроизохинолинила, хиназолинила, хиноксалинила, фталазинила, циннолинила, нафтиридинила, бензофуранила, дигидробензофуранила, бензотиенила, дигидробензотиенила, индолила, индолинила, индазолила, изоиндолила, бензимидазолила, бензоксазолила, бензизоксазолила, бензотиазолила, бензизотиазолила, бензотриазолила, бензоксадиазолила, бензотиадиазолила, пирролопиридинила, фуропиридинила, тиенопиридинила, имидазопиридинила, оксазолопиридинила, тиазолопиридинила, пиразолопиридинила, изоксазолопиридинила, изотиазолопиридинила;Rозначает группу, выбранную из атомов галогена, групп циа�
Claims (12)
1. Соединение, отвечающее общей формуле (I)
в которой
А выбран из одной или нескольких групп X, Y и/или Z;
X означает метиленовую группу, необязательно замещенную одной или двумя группами, представляющими C1-6-алкил, C3-7-циклоалкил или C3-7-циклоалкил-C1-3-алкилен;
Y означает или C2-алкениленовую группу, необязательно замещенную одной или двумя группами, представляющими C1-6-алкил, C3-7-циклоалкил или C3-7-циклоалкил-C1-3-алкилен; или C2-алкиниленовую группу;
Z означает группу формулы:
m означает целое число от 1 до 5;
p и q означают целые числа и определены так, что p+q является числом от 1 до 5;
n означает целое число от 1 до 7;
R1 означает группу R2, необязательно замещенную одной или несколькими группами R3 и/или R4;
R2 означает группу, выбранную из пиридинила, пиримидинила, пиридазинила, пиразинила, триазинила, пирролила, фуранила, тиенила, имидазолила, оксазолила, тиазолила, пиразолила, изоксазолила, изотиазолила, оксадиазолила, тиадиазолила, триазолила, тетразолила, нафтила, хинолинила, тетрагидрохинолинила, изохинолинила, тетрагидроизохинолинила, 2-оксо-3,4-дигидрохинолинила, 1-оксо-3,4-дигидроизохинолинила, хиназолинила, хиноксалинила, фталазинила, циннолинила, нафтиридинила, бензофуранила, дигидробензофуранила, бензотиенила, дигидробензотиенила, индолила, индолинила, индазолила, изоиндолила, бензимидазолила, бензоксазолила, бензизоксазолила, бензотиазолила, бензизотиазолила, бензотриазолила, бензоксадиазолила, бензотиадиазолила, пирролопиридинила, фуропиридинила, тиенопиридинила, имидазопиридинила, оксазолопиридинила, тиазолопиридинила, пиразолопиридинила, изоксазолопиридинила, изотиазолопиридинила;
R3 означает группу, выбранную из атомов галогена, групп циано, нитро, C1-6-алкил, C3-7-циклоалкил, C1-6-алкокси, гидроксил, C1-6-тиоалкил, C1-6-фторалкил, C1-6-фторалкокси, C1-6-фтортиоалкил, NR5R6, NR5COR6, NR5CO2R6, NR5SO2R6, COR5, CO2R5, CONR5R6, SO2R5, SO2R5R6, -О-(C1-3-алкилен)-O и фенил, причем фенильная группа необязательно замещена одним или несколькими атомами галогена;
R4 означает группу, выбранную из групп: фенил, фенилокси, бензилокси, нафтил, пиридинил, пиримидинил, пиридазинил, пиразинил; причем группа или группы R4 могут быть замещены одной или несколькими группами R3, одинаковыми или отличающимися друг от друга;
R5 и R6 независимо друг от друга означают атом водорода или C1-6-алкильную группу, или вместе с атомом или атомами, с которыми они связаны, образуют цикл, выбранный из азетидинового, пирролидинового, пиперидинового, морфолинового, тиоморфолинового, азепинового или пиперазинового цикла, причем этот цикл необязательно замещен C1-6-алкильной или бензильной группой;
R7 означает атом водорода или C1-6-алкильную группу;
R8 означает атом водорода или группу C1-6-алкил, C3-7-циклоалкил, C3-7-циклоалкил-C1-3-алкилен;
в виде основания, кислотно-аддитивной соли, гидрата или сольвата.
2. Соединение формулы (I) по п. 1, отличающееся тем, что
А выбран из одной или нескольких групп X и/или Y;
X означает метиленовую группу;
Y означает C2-алкиниленовую группу;
n означает целое число от 1 до 5;
R1 означает группу R2, необязательно замещенную одной или несколькими группами R3 и/или R4;
R2 означает группу, выбранную из пиридинила, пиримидинила, пиридазинила, имидазолила, оксазолила, пиразолила, изоксазолила, оксадиазолила, нафтила, хинолинила, изохинолинила, дигидроизохинолинила, 2-оксо-3,4-дигидрохинолинила, индолила, бензимидазолила, пирролопиридинила;
R3 означает группу, выбранную из атомов галогена, групп C1-6-алкил, C3-7-циклоалкил, C1-6-алкокси, NR5R6 и фенил;
R4 означает группу, выбранную из групп: фенил, нафтил, пиридинил; причем группа или группы R4 могут быть замещены одной или несколькими группами R3, одинаковыми или отличающимися друг от друга;
R5 и R6 независимо друг от друга означают C1-6-алкильную группу;
R7 означает атом водорода или C1-6-алкильную группу;
R8 означает атом водорода или группу C1-6-алкил, C3-7-циклоалкил, C3-7-циклоалкил-C1-3-алкилен;
в виде основания, кислотно-аддитивной соли, гидрата или сольвата.
3. Соединение формулы (I) по п. 1 или 2, отличающееся тем, что R2 означает группу, выбранную из пиридинила, пиримидинила, оксазолила, изоксазолила, нафтила, хинолинила, изохинолинила.
4. Соединение формулы (I) по п. 1 или 2, отличающееся тем, что R7 означает атом водорода; R8 означает атом водорода или C1-6-алкильную группу,
в виде основания, кислотно-аддитивной соли, гидрата или сольвата.
5. Способ получения соединения формулы (I) по любому из пп. 1-4, включающий стадию, состоящую в преобразовании эфира-карбамата общей формулы (IV)
в которой A, n, R1 и R7 такие, как определено в формуле (I) по п. 1, и R означает метильную или этильную группу,
путем аминолиза амином общей формулы R8NH2, в которой R8 таково, как определено в формуле (I) по п. 1.
6. Способ получения соединения формулы (I) по любому из пп. 1-4, включающий стадию,
состоящую в преобразовании производного оксазолидиндиона общей формулы (VII),
в которой A, n, R1 и R7 такие, как определено в формуле (I) по п. 1,
путем аминолиза амином общей формулы R8NH2, в которой R8 таково, как определено в формуле (I) по п. 1.
7. Соединение, отвечающее общей формуле (IV),
в которой A, n, R1 и R7 такие, как определено в формуле (I) по п. 1, и R означает метильную или этильную группу, за исключением следующих соединений:
этил-2-[({[2-(5-гидрокси-1H-индол-3-ил)этил]амино}карбонил)окси]пропаноат;
этил-2-[({[2-[5-(фенилметокси)-1H-индол-3-ил]этил}амино)карбонил]окси]пропаноат.
8. Соединение, отвечающее общей формуле (VII),
в которой A, n, R1 и R7 такие, как определено в формуле (I) по п. 1, за исключением следующих соединений:
йодид 2-[2-(2,4-диоксо-3-оксазолидинил)этил]-1-метилпиридиния;
йодид 2-[2-(2,4-диоксо-3-оксазолидинил)этил]-5-этил-1-метилпиридиния;
йодид 4-[2-(2,4-диоксо-3-оксазолидинил)этил]-1-метилпиридиния;
гидрохлорид 5-метил-3-[2-(4-пиридинил)этил]-2,4-оксазолидиндиона;
гидрохлорид 5-метил-3-[2-(2-пиридинил)этил]-2,4-оксазолидиндиона;
3-(5-имидазо[1,2-a]пиридин-5-илпентил)-2,4-оксазолидиндион;
3-[2-(5-метил-4-тиазолил)этил]-2,4-оксазолидиндион;
3-[2-(1H-пиррол-2-ил)этил]-2,4-оксазолидиндион;
3-[2-(2-тиенил)этил]-2,4-оксазолидиндион;
3-[3-(2-тиенил)пропил]-2,4-оксазолидиндион;
3-[4-(2-тиенил)бутил]-2,4-оксазолидиндион;
5-метил-3-[2-(2-тиенил)этил]-2,4-оксазолидиндион;
5-этил-3-[2-(2-тиенил)этил]-2,4-оксазолидиндион;
3-[2-(3-тиенил)этил]-2,4-оксазолидиндион;
3-[2-(5-метил-2-тиенил)этил]-2,4-оксазолидиндион;
3-[2-(5-ацетил-2-тиенил)этил]-2,4-оксазолидиндион;
3-[2-(5-бром-2-тиенил)этил]-2,4-оксазолидиндион;
5-[2-(2,4-диоксо-3-оксазолидинил)этил]-2-тиофенкарбоксальдегид;
3-[3-[1-индолинил)пропил]-2,4-оксазолидиндион;
3-[3-[1-индолинил)пропил]-5-метил-2,4-оксазолидиндион;
3-[2-(2-пиридинил)этил]-2,4-оксазолидиндион;
3-[2-(5-этил-2-пиридинил)этил]-5-метил-2,4-оксазолидиндион;
5-этил-3-[2-(5-этил-2-пиридинил)этил]-2,4-оксазолидиндион;
3-[2-(5-этил-2-пиридинил)этил]-5-изопропил-2,4-оксазолидиндион;
3-[2-(4-пиридинил)этил]-2,4-оксазолидиндион;
5-этил-3-[2-(4-пиридинил)этил]-2,4-оксазолидиндион;
5-этил-3-[2-(2-пиридинил)этил]-2,4-оксазолидиндион;
5-изопропил-3-[2-(4-пиридинил)этил]-2,4-оксазолидиндион;
5-изопропил-3-[2-(2-пиридинил)этил]-2,4-оксазолидиндион;
3-[2-(5-этил-2-пиридинил)этил]-2,4-оксазолидиндион.
9. Фармацевтическая композиция, содержащая по меньшей мере одно соединение формулы (I) по любому из пп. 1-4 в виде фармацевтически приемлемого основания, соли, гидрата или сольвата и необязательно один или несколько фармацевтически приемлемых эксципиентов.
10. Применение соединения формулы (I) по любому из пп. 1-4 в виде фармацевтически приемлемого основания, соли, гидрата или сольвата в качестве лекарственного средства.
11. Применение соединения формулы (I) по любому из пп. 1-4 в виде фармацевтически приемлемого основания, соли, гидрата или сольвата для получения лекарственного средства, предназначенного для предупреждения или лечения патологии, в которую вовлечены эндогенные каннабиоиды и/или любые другие субстраты, метаболизированные ферментом FAAH.
12. Применение соединения формулы (I) по любому из пп. 1-4 в виде фармацевтически приемлемого основания, соли, гидрата или сольвата, для получения лекарственного средства, предназначенного для предупреждения или лечения острых или хронических болей, головокружений, рвоты, тошноты, нарушений пищевого поведения, неврологических и психиатрических патологий, острых или хронических нейродегенеративных заболеваний, эпилепсии, нарушений сна, сердечно-сосудистых заболеваний, почечной ишемии, рака, расстройств иммунной системы, аллергических заболеваний, инфекционных паразитарных, вирусных или бактериальных заболеваний, воспалительных заболеваний, остеопороза, глазных болезней, болезней легких, желудочно-кишечных заболеваний или недержания мочи.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0401949A FR2866886B1 (fr) | 2004-02-26 | 2004-02-26 | Derives d'aryl-et d'heteroaryl-akylcarbamates, leur preparation et leur application en therapeutique |
FR0401949 | 2011-04-26 |
Publications (2)
Publication Number | Publication Date |
---|---|
RU2006134026A true RU2006134026A (ru) | 2008-04-10 |
RU2364586C2 RU2364586C2 (ru) | 2009-08-20 |
Family
ID=34834066
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2006134026/04A RU2364586C2 (ru) | 2004-02-26 | 2005-02-25 | Производные гетероарилалкилкарбаматов, их получение и их применение в качестве ингибиторов фермента faah |
Country Status (29)
Country | Link |
---|---|
US (3) | US7645757B2 (ru) |
EP (2) | EP1720829B1 (ru) |
JP (1) | JP4824668B2 (ru) |
KR (1) | KR20070011297A (ru) |
CN (1) | CN1926097B (ru) |
AR (1) | AR047973A1 (ru) |
AT (1) | ATE445592T1 (ru) |
AU (1) | AU2005223423B2 (ru) |
BR (1) | BRPI0508193A (ru) |
CA (1) | CA2554609A1 (ru) |
CY (1) | CY1109716T1 (ru) |
DE (1) | DE602005017122D1 (ru) |
DK (1) | DK1720829T3 (ru) |
ES (1) | ES2334449T3 (ru) |
FR (1) | FR2866886B1 (ru) |
HK (1) | HK1101759A1 (ru) |
HR (1) | HRP20100017T1 (ru) |
IL (1) | IL177329A (ru) |
MA (1) | MA28367A1 (ru) |
NO (1) | NO20064329L (ru) |
NZ (1) | NZ550008A (ru) |
PL (1) | PL1720829T3 (ru) |
PT (1) | PT1720829E (ru) |
RS (1) | RS51246B (ru) |
RU (1) | RU2364586C2 (ru) |
SI (1) | SI1720829T1 (ru) |
TW (1) | TW200533637A (ru) |
WO (1) | WO2005090292A1 (ru) |
ZA (1) | ZA200606724B (ru) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2866884B1 (fr) * | 2004-02-26 | 2007-08-31 | Sanofi Synthelabo | Derives d'aryl-et d'heteroaryl-piperidinecarboxylates, leur preparation et leur application en therapeutique |
FR2866885B1 (fr) * | 2004-02-26 | 2007-08-31 | Sanofi Synthelabo | Derives de piperidinylalkylcarbamates, leur prepation et leur application en therapeutique |
EP2141150B1 (en) | 2007-04-26 | 2013-12-11 | Takeda Pharmaceutical Company Limited | Bicyclic compound and pharmaceutical use thereof |
WO2009070497A1 (en) * | 2007-11-28 | 2009-06-04 | Smithkline Beecham Corporation | SEH AND 11 β-HSD1 INHIBITORS AND THEIR USE |
KR101799429B1 (ko) * | 2010-05-03 | 2017-11-21 | 에스케이바이오팜 주식회사 | 신경 세포 사멸 또는 신경 퇴화를 억제하기 위한 약학적 조성물 |
Family Cites Families (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2866734A (en) * | 1956-12-05 | 1958-12-30 | Us Vitamin Corp | 3-pyridylethyl 2, 4-oxazolidinediones and process |
US3054794A (en) * | 1958-01-17 | 1962-09-18 | Us Vitamin Pharm Corp | Process for preparing 3-(aminoalkyl)-oxazolidine-2, 4-diones |
US3742022A (en) * | 1967-05-08 | 1973-06-26 | A Verbiscar | Carbamate esters of physiologically active ph enenthylamines |
US3876661A (en) * | 1971-03-02 | 1975-04-08 | Anthony J Verbiscar | Carbamate esters of serotonin and analogs |
DE69833791D1 (de) * | 1997-11-24 | 2006-05-04 | Scripps Research Inst | Hemmer der "gap junction communication" |
US6509366B2 (en) * | 2000-01-18 | 2003-01-21 | Neurogen Corporation | Substituted imidazoles as selective modulators of Bradykinin B2 receptors |
CA2445294A1 (en) * | 2001-04-27 | 2002-11-07 | Bristol-Myers Squibb Company | Bisarylimidazolyl fatty acid amide hydrolase inhibitors |
JP4567439B2 (ja) * | 2002-04-27 | 2010-10-20 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | カルボン酸アミド |
FR2843964B1 (fr) * | 2002-08-29 | 2004-10-01 | Sanofi Synthelabo | Derives de dioxane-2-alkylcarbamates, leur preparation et leur application en therapeutique |
UA80841C2 (en) * | 2002-10-07 | 2007-11-12 | Univ California | Fatty acid amide hydrolase inhibitors, pharmaceutical composition (variants) and method to treat appetite disorders, glaucoma, pain, and related neurological disorders (variants) |
CN1703407A (zh) * | 2002-10-08 | 2005-11-30 | 斯克里普斯研究学院 | 脂肪酸酰胺水解酶抑制剂 |
US7309701B2 (en) * | 2002-11-19 | 2007-12-18 | Sanofi-Aventis Deutschland Gmbh | Pyridazinone derivatives as pharmaceuticals and pharmaceutical compositions containing them |
FR2850377B1 (fr) * | 2003-01-23 | 2009-02-20 | Sanofi Synthelabo | Derives d'arylalkylcarbamates, leur preparation et leur application en therapeutique |
FR2854633B1 (fr) * | 2003-05-07 | 2005-06-24 | Sanofi Synthelabo | Derives de piperidinyl-et piperazinyl-alkylcarbamates, leur preparation et leur application en therapeutique |
UA82695C2 (ru) * | 2003-06-06 | 2008-05-12 | Нисан Кемикал Индастриз, Лтд. | Гетероароматические соединения как активаторы рецептора тромбопоэтина |
US20050032747A1 (en) * | 2003-07-01 | 2005-02-10 | Wilmin Bartolini | COX-2 and FAAH inhibitors |
NZ546365A (en) * | 2003-10-08 | 2010-01-29 | Vertex Pharma | Modulators of ATP-binding cassette transporters containing cycloalkyl or pyranyl groups |
FR2866885B1 (fr) * | 2004-02-26 | 2007-08-31 | Sanofi Synthelabo | Derives de piperidinylalkylcarbamates, leur prepation et leur application en therapeutique |
EP1574511A1 (en) * | 2004-03-03 | 2005-09-14 | Bayer CropScience S.A. | 2-Pyridinylethylcarboxamide derivatives and their use as fungicides |
WO2007017728A2 (en) * | 2005-08-05 | 2007-02-15 | Orchid Research Laboratories Limited | Novel heterocyclic compounds |
CA2623317A1 (en) * | 2005-09-22 | 2007-03-29 | Sanofi-Aventis | Amino-alkyl-amide derivatives as ccr3 receptor liquids |
FR2894578B1 (fr) * | 2005-12-12 | 2008-02-01 | Sanofi Aventis Sa | Derives heterocycliques, leur preparation et leur application en therapeutique. |
EP1983971A4 (en) * | 2006-01-25 | 2010-11-24 | Synta Pharmaceuticals Corp | SUBSTITUTED AROMATIC COMPOUNDS FOR USE AGAINST INFLAMMATION AND IMMUNE DISORDERS |
JO2754B1 (en) * | 2006-12-21 | 2014-03-15 | استرازينكا ايه بي | Amylendazoleil derivatives for the treatment of glucocorticoid-mediated disorders |
US9549982B2 (en) * | 2009-11-23 | 2017-01-24 | Foundational Biosystems, Llc | Ultra low dose nutraceutical compositions for enhancing sleep quality and treating sleep disorders |
-
2004
- 2004-02-26 FR FR0401949A patent/FR2866886B1/fr not_active Expired - Fee Related
-
2005
- 2005-02-25 DK DK05732902.1T patent/DK1720829T3/da active
- 2005-02-25 PT PT05732902T patent/PT1720829E/pt unknown
- 2005-02-25 TW TW094105874A patent/TW200533637A/zh unknown
- 2005-02-25 JP JP2007500260A patent/JP4824668B2/ja not_active Expired - Fee Related
- 2005-02-25 ES ES05732902T patent/ES2334449T3/es active Active
- 2005-02-25 WO PCT/FR2005/000451 patent/WO2005090292A1/fr active Application Filing
- 2005-02-25 AT AT05732902T patent/ATE445592T1/de active
- 2005-02-25 ZA ZA200606724A patent/ZA200606724B/xx unknown
- 2005-02-25 RU RU2006134026/04A patent/RU2364586C2/ru not_active IP Right Cessation
- 2005-02-25 NZ NZ550008A patent/NZ550008A/en unknown
- 2005-02-25 CN CN2005800058656A patent/CN1926097B/zh not_active Expired - Fee Related
- 2005-02-25 EP EP05732902A patent/EP1720829B1/fr active Active
- 2005-02-25 EP EP09172706A patent/EP2251324A1/fr not_active Withdrawn
- 2005-02-25 CA CA002554609A patent/CA2554609A1/fr not_active Abandoned
- 2005-02-25 DE DE602005017122T patent/DE602005017122D1/de active Active
- 2005-02-25 PL PL05732902T patent/PL1720829T3/pl unknown
- 2005-02-25 KR KR1020067017250A patent/KR20070011297A/ko active IP Right Grant
- 2005-02-25 SI SI200530882T patent/SI1720829T1/sl unknown
- 2005-02-25 BR BRPI0508193-9A patent/BRPI0508193A/pt not_active IP Right Cessation
- 2005-02-25 AU AU2005223423A patent/AU2005223423B2/en not_active Ceased
- 2005-02-25 RS RSP-2010/0011A patent/RS51246B/sr unknown
- 2005-05-24 AR ARP050100666A patent/AR047973A1/es unknown
-
2006
- 2006-08-07 IL IL177329A patent/IL177329A/en not_active IP Right Cessation
- 2006-08-14 US US11/464,355 patent/US7645757B2/en not_active Expired - Fee Related
- 2006-08-22 MA MA29285A patent/MA28367A1/fr unknown
- 2006-09-25 NO NO20064329A patent/NO20064329L/no not_active Application Discontinuation
-
2007
- 2007-08-31 HK HK07109485.6A patent/HK1101759A1/xx not_active IP Right Cessation
-
2009
- 2009-11-24 US US12/625,125 patent/US20100069405A1/en not_active Abandoned
-
2010
- 2010-01-11 CY CY20101100030T patent/CY1109716T1/el unknown
- 2010-01-11 HR HR20100017T patent/HRP20100017T1/hr unknown
-
2011
- 2011-06-09 US US13/156,551 patent/US20110237595A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11248010B2 (en) | Compounds, compositions, and methods for modulating CFTR | |
RU2006134037A (ru) | Производные арил-и гетероарилпиперидинкарбоксилатов, их получение и их применение в качестве ингибиторов фермента faah | |
JP5452594B2 (ja) | アルキルチアゾールカルバメート誘導体、この調製、およびfaah酵素阻害剤としてのこの使用 | |
RU2006134047A (ru) | Производные алкилпиперазин- и алкилгомопиперазинкарбоксилатов, их получение и применение в качестве ингибиторов фермента faah | |
RU2006134025A (ru) | Производные пиперидиналкилкарбаматов, их получение и их применение в качестве ингибиторов фермента faah | |
JP2007524704A5 (ru) | ||
US20050209223A1 (en) | Novel antibacterial compounds: process for their preparation and pharmaceutical compositions containing them | |
US8648103B2 (en) | Nitrogen-containing aromatic heterocyclyl compound | |
RU2006134026A (ru) | Производные гетероарилалкилкарбаматов, их получение и их применение в качестве ингибиторов фермента faah | |
JP2007524706A5 (ru) | ||
WO2002002542A1 (en) | Five-membered-ring compound | |
JP2006517218A5 (ru) | ||
JP2007507474A5 (ru) | ||
JP2007524705A5 (ru) | ||
KR20110083743A (ko) | 알킬-헤테로사이클의 카르바메이트 유도체, 그의 제조법 및 그의 치료 용도 | |
JP2007510629A5 (ru) | ||
US20060173043A1 (en) | Use of novel 2-oxo-heterocyclic compounds and the pharmaceutical compositions comprising the same | |
JP2866277B2 (ja) | アルキレンジアミン誘導体 | |
MXPA06009396A (en) | Derivatives of heteroaryl-alkylcarbamates, preparation method thereof and use of same as faah enzyme inhibitors | |
FR2463766A1 (fr) | Nouvelles 1(2h)-isoquinolones, utiles notamment comme analgesiques | |
US20150336940A1 (en) | Therapeutic substituted pyrroles | |
AU2011204768A1 (en) | Derivatives of heteroaryl-alkylcarbamates, preparation method thereof and use of same as FAAH enzyme inhibitors | |
MXPA06009626A (en) | Derivatives of piperidinylalkylcarbamates, preparation method thereof and use of same as faah enzyme inhibitors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20120226 |